FBT - First Trust NYSE Arca Biotechnology Index Fund
| Previous Close | 131.05 |
| Open | 132.08 |
| Bid | 130.30 x 900 |
| Ask | 132.70 x 800 |
| Day's Range | 132.06 - 134.03 |
| 52 Week Range | 113.43 - 159.85 |
| Volume | 73,899 |
| Avg. Volume | 88,092 |
| Net Assets | 2.84B |
| NAV | 134.04 |
| PE Ratio (TTM) | N/A |
| Yield | 0.00% |
| YTD Return | 7.88% |
| Beta (3Y Monthly) | 1.58 |
| Expense Ratio (net) | 0.57% |
| Inception Date | 2006-06-19 |
- Zacks
Biotech ETFs in Focus on Impressive Q2 Earnings Results
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.
- ETF Trends
Biotech ETFs Strengthen After Judge Blocks Trump’s Drug Pricing Rule
Biotechnology stocks and sector-related exchange traded funds stood out on Tuesday after a U.S. District Court overruled President Donald Trump’s wishes to require drugmakers list prices on television ...
- Zacks
ETF & Stock Winners of Longest US Economic Expansion
The U.S. economy has stepped into the 11th year of the expansion, exhibiting the longest expansion in history. These winning ETFs and stocks will rally further.
- Zacks
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
- Zacks
Biotech ETFs in Focus on String of Q1 Earnings Beats
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
- Zacks
Will Biotech ETFs Continue to Rally in Q1 Earnings?
Here we study the possible impact of some major Q1 earnings releases on certain biotech ETFs .
- Zacks
Health Day Checkup of Medical ETFs: 5 Top Picks
M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.
- Zacks
Top-Performing ETFs Of The 10-Year Bull-Run
Learn more about the ETFs that crushed the broad indexes during the ten-year bull-run.
- Zacks
10 Top-Ranked ETFs Leading the 10-Year Bull Run
We have presented a bunch of top-performing ETFs of the 10-year bull market that will continue to outperform in the coming months given that these have a Zacks ETF Rank 1 (Strong Buy) or 2 (Buy).
- Zacks
4 Sector ETFs That Crushed S&P 500 in Decade-Old Bull Run
These sector ETFs emerged winners in the 10-year old bull market.
- Investor's Business Daily
Biotech ETF Among Top Opportunities For Stock Market Investors
Though volatility may persist this year, Churchill Management Group says moneymaking opportunities may exist even for cautious stock market investors.
- Zacks
Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.
- Zacks
What's Behind the Biotech ETF Rally to Start 2019?
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.
- Investor's Business Daily
Biotech ETFS: How To Pick Biotech Stock Winners And Avoid Volatility In 2019
Biotech ETFs allow investors to buy into a basket of biotech stocks, rather than trying to select specific winners. The best biotech ETFs are diverse, with less volatility.
Market RealistWhy Exelixis Stock Soared 46% in November
Exelixis stock rose from $13.87 at the close of markets on October 31, 2018, to reach $20.31 at the close of market on November 30, 2018, a ~46% increase over the last month. Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29, 2018. Exelixis stock experienced solid growth after the company released its third-quarter financial results on November 1, 2018.
Market RealistHow BioMarin Pharmaceutical’s Financials Look in November
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year, a ~19% YoY increase. BioMarin Pharmaceutical reported net revenues of $391.7 million in the third quarter, which reflected ~17% YoY growth.
- InvestorPlace
7 Biotech ETFs to Consider for 2019
Market RealistA Look at Exelixis’s Financials in November
Exelixis reported revenues of $625.2 million in the first nine months of this year compared to $332.4 million in the same period the prior year. In the third quarter, Exelixis generated revenues of $162.9 million from product sales compared to $96.4 million in the third quarter of 2017, reflecting ~69% YoY growth. Exelixis generated $62.5 million in collaboration revenues in the third quarter compared to $56.1 million in the third quarter of 2017.
- Market Realist
Analysts Expect Incyte to Report Revenue Growth in Third Quarter
As discussed earlier, analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018. The below graph compares the revenues of Incyte since the first quarter of 2017 and estimates for the third quarter of 2018. Incyte’s revenue stream includes product sales, royalty revenues, and other revenues from collaborations. Incyte acquired the commercial rights for Iclusig from Ariad Pharmaceuticals in 2016.
Market RealistAlkermes in the Third Quarter: A Performance Overview
Alkermes (ALKS) reported its third-quarter financial results on October 23. It generated net revenues of $248.7 million compared to $217.4 million in the third quarter of 2017. That was a 14% YoY (year-over-year) growth.
Market RealistA Financial Overview of Ionis Pharmaceuticals in October
Ionis Pharmaceuticals generated second-quarter revenues of $118.0 million compared to $122.3 million in the second quarter of 2017, which reflected ~15.0% YoY (year-over-year) growth. In the first half, Ionis Pharmaceuticals reported revenues of $262.2 million, compared to $228.1 million in the first half of 2017.
- Market Realist
Ionis Pharmaceuticals’ Revenue Stream
Ionis Pharmaceuticals’ (IONS) revenue stream is segregated into two segments: Research and Development revenues from the collaborative agreements with other companies, and Commercial Revenues. Commercial Revenues include licensing and royalty revenues and Spinraza royalties. The chart below compares the revenues for Ionis Pharmaceuticals since the first quarter of 2017.
Market RealistHow Vertex Pharmaceuticals Is Positioned Financially
In the first half of this year, Vertex Pharmaceuticals’ (VRTX) revenue grew ~40% YoY (year-over-year) to $1.4 billion from $994.6 million. Kalydeco, Orkambi, and Symdeko saw revenue of $253.0 million, $311.0 million, and $186.0 million, respectively, in Q2 2018, compared with $250.0 million, $354.0 million, and $34.0 million, respectively, in Q1 2018. Vertex’s revenue growth could boost the First Trust NYSE Arca Biotechnology Index ETF (FBT), of which Vertex comprises ~3.33%.
Market RealistLook at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).
- Investor's Business Daily
Top ETFs: First Trust Biotech Beats Larger Rivals
Smaller is better for First Trust NYSE Arca Biotechnology Index Fund, which has become one of the top ETFs by using a concentrated portfolio.
